Beximco Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beximco Pharmaceuticals Ltd.
Beximco Profit Tumble Continues Amid Hostile Macro Climate
Beximco faced another quarter of declining profits despite growing revenue, as external headwinds including increased production costs took their toll on the firm.
Expected Drop In COVID-19 Vaccine Sales Hits Beximco’s Bottom Line
The absence of any income from distributing AstraZeneca’s COVID-19 vaccine led to Beximco’s pre-tax profit dropping by 13% in the first six months of its financial year ending in June 2023. However, profits after tax actually rose slightly when discounting last year’s COVID-19 vaccine impact.
International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation
Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.
A Year Of Paxlovid - Where Is The Licensed Generic?
A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.
- Generic Drugs
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.